# Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

> **NCT01652157** · — · TERMINATED · sponsor: **AbbVie** · enrollment: 17 (actual)

## Conditions studied

- Fibrosing Colonopathy

## Interventions

- **BIOLOGICAL:** ULTRESA
- **BIOLOGICAL:** PANCREAZE
- **BIOLOGICAL:** CREON
- **BIOLOGICAL:** ZENPEP
- **BIOLOGICAL:** other non-sponsor pancreatic enzyme replacement therapy
- **BIOLOGICAL:** PERTZYE
- **OTHER:** No pancreatic enzyme replacement therapy

## Key facts

- **NCT ID:** NCT01652157
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07-31
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-04-08
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2021-03-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652157, "Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT01652157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*